COVID-19
The CRF has supported many COVID-19 related studies over the past year. These studies range from investigator led studies where we are trying to understand more about the disease and how it affects people to clinical trials where we are trying to determine the best treatment for patients in either an inpatient or intensive care setting.
| Study Name | Study Title Study | Study Type | Sponsor | Sponsor Type |
|---|---|---|---|---|
| SOLIDARITY | An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care (Public health emergency SOLIDARITY trial) | Clinical trial (NCT04647669) | WHO | Non-commercial: Hospital |
| Covid Encephalopathy | Analysing blood-brain barrier integrity to inform on protection from CoVID-19 associated encephalopathy. | Observational | Academic | Non-commercial: Academic |
| EU-SolidAct/Bari-SolidAct | European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial / Efficacy and Safety of baricitinib for the treatment of severe COVID-19 | Clinical trial (NCT04891133) | Oslo University Hospital | Non-commercial: Hospital |
| National Covid Biobank | National Irish Covid-19 Biobank NICB Project | Observational | NICB | Non-commercial: Hospital |
| EU-COVAT-2 BOOSTAVAC | An International Multicentre, Phase 2, Randomised, Adaptive Protocol to determine the need for, optimal timing of and immunogenicity of administering a 4 th homologous mRNA vaccination dose against SARS-CoV-2 in the general population (18+ years) already vaccinated against SARS-CoV-2 | Clinical trial (2021-004889-35) | Academic | Non-commercial: Academic |
| Study Name | Study Title Study | Study Type | Sponsor | Sponsor Type |
|---|---|---|---|---|
| Covid Immune response in ICU | Characterising the immune response in Covid-19 infection: towards identifying prognostic indicators of disease severity | Observational | N/A | N/A |
| Sprint-Sari | Short Period Incidence study of severe Acute Respiratory Infection | Observational (NCT02498587) | N/A | N/A |
| Tropic | Technology Assisted Solutions for the Recognition of Objective Physiological Indicators of post-COVID-19 Fatigue | Obervational (NCT05027724) | Academic | Non Commercial: Academic |
| Discovery | Multi-centre, adaptive, randomised trial of the safety and efficacy of treatments of Covid-19 in hospitalised adults | Clinical trial (NCT04315948) | National (Government agency) | Non-commercial: Hospital |
| Decompress | Defining the disease course and immune profile of COVID-19 in the immunosuppressed patient | Observational | Academic | Non Commercial: Academic |
| Alfa-1 | A randomized double blind placebo- controlled, pilot trial of intravenous plasma-purified alpha 1 antitrypsin for severe COVID-19 illness | Clinical Trial (2020-001391-15) | RCSI | Non-commercial: Academic |